{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:32Z","timestamp":1787614832927,"version":"build-2736575974"},"reference-count":44,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Australian Government Research Training Program Fees Offset"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Nonclassic congenital adrenal hyperplasia (NCCAH) requires exclusion before diagnosing polycystic ovary syndrome (PCOS). Increasing use of liquid chromatography and tandem mass spectrometry (LC-MS\/MS) necessitates revision of immunoassay-based criteria for NCCAH. Measurement of 21-deoxycortisol (21DF) may simplify the diagnosis of heterozygosity (HTZ), the presence of 1 affected CYP21A2 allele, which currently relies on complex molecular studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>We aimed to determine LC-MS\/MS-specific criteria for NCCAH and HTZ and compare the diagnostic accuracy of 21DF and 17-hydroxyprogesterone (17OHP).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A cross-sectional study involving 99 hyperandrogenic females was performed. We identified females who had undergone both a synacthen stimulation test (SST) and CYP21A2 genotyping from 2010 to 2017, and prospectively recruited females referred for an SST to investigate hyperandrogenic symptoms from 2017 to 2021. Steroids were compared between genetically confirmed NCCAH, HTZ, and PCOS. Optimal 17OHP and 21DF thresholds for HTZ and NCCAH were determined by receiver operating characteristic analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Basal 17OHP, stimulated 17OHP, and 21DF were measured in 99, 85, and 42 participants, respectively. Optimal thresholds for NCCAH were 3.0 nmol\/L and 20.7 nmol\/L for basal and stimulated 17OHP, respectively. Basal and stimulated 21DF thresholds of 0.31 nmol\/L and 13.3 nmol\/L provided 100% sensitivity with specificities of 96.8% and 100% for NCCAH, respectively. Diagnostic thresholds for HTZ of 8.0 nmol\/L, 1.0 nmol\/L, and 13.6 for stimulated 17OHP, 21DF, and the ratio (21DF + 17OHP)\/cortisol each provided 100% sensitivity with specificities of 80.4%, 90.5%, and 85.0%, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>LC-MS\/MS-specific 17OHP thresholds for NCCAH are lower than those based on immunoassay. LC-MS\/MS-quantified 17OHP and 21DF accurately discriminate HTZ and NCCAH from PCOS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad377","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T09:55:28Z","timestamp":1687773328000},"page":"e1560-e1570","source":"Crossref","is-referenced-by-count":14,"title":["Serum 21-Deoxycortisol for Diagnosis of Nonclassic Congenital Adrenal Hyperplasia in Women With Androgen Excess"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7525-0587","authenticated-orcid":false,"given":"Jennifer L","family":"Ng","sequence":"first","affiliation":[{"name":"Keogh Institute for Medical Research, Sir Charles Gairdner Hospital , Nedlands, Western Australia 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ee Mun","family":"Lim","sequence":"additional","affiliation":[{"name":"PathWest Laboratory Medicine, Department of Chemical Pathology, QEII Medical Centre , Nedlands, Western Australia 6009 , Australia"},{"name":"Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital , , Nedlands, Western Australia 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"PathWest Laboratory Medicine, Department of Chemical Pathology, QEII Medical Centre , Nedlands, Western Australia 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Beilby","sequence":"additional","affiliation":[{"name":"School of Biomedical Sciences, The University of Western Australia , Crawley, Western Australia 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F","family":"Watts","sequence":"additional","affiliation":[{"name":"Cardiometabolic Service, Departments of Cardiology and Internal Medicine, Royal Perth Hospital , Perth, Western Australia 6000 , Australia"},{"name":"Medical School, University of Western Australia , Crawley, Western Australia 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne J","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital , , Nedlands, Western Australia 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bronwyn G A","family":"Stuckey","sequence":"additional","affiliation":[{"name":"Keogh Institute for Medical Research, Sir Charles Gairdner Hospital , Nedlands, Western Australia 6009 , Australia"},{"name":"Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital , , Nedlands, Western Australia 6009 , Australia"},{"name":"Medical School, University of Western Australia , Crawley, Western Australia 6009 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,6,26]]},"reference":[{"issue":"5","key":"2023111712400395200_dgad377-B1","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/humupd\/dmx014","article-title":"Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women","volume":"23","author":"Carmina","year":"2017","journal-title":"Hum Reprod Update"},{"key":"2023111712400395200_dgad377-B2","first-page":"245","article-title":"Congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"21","author":"White","year":"2000","journal-title":"Endocr Rev"},{"issue":"11","key":"2023111712400395200_dgad377-B3","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2023111712400395200_dgad377-B4","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1210\/jc.2013-1381","article-title":"Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women","volume":"98","author":"Fanelli","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023111712400395200_dgad377-B5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/gim.2017.46","article-title":"Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians","volume":"19","author":"Hannah-Shmouni","year":"2017","journal-title":"Genet Med"},{"issue":"6","key":"2023111712400395200_dgad377-B6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/1043-2760(90)90068-E","article-title":"Newborn screening, prenatal diagnosis, and prenatal treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"1","author":"Pang","year":"1990","journal-title":"Trends Endocrinol Metab"},{"key":"2023111712400395200_dgad377-B7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105554","article-title":"Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia","volume":"198","author":"Guarnotta","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"2023111712400395200_dgad377-B8","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/jcem.84.5.5683","article-title":"High incidence of molecular defects of the CYP21 gene in patients with premature adrenarche","volume":"84","author":"Dacou-Voutetakis","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023111712400395200_dgad377-B9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2265.2006.02521.x","article-title":"Hyperandrogenism in carriers of CYP21 mutations: the role of genotype","volume":"64","author":"Admoni","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2023111712400395200_dgad377-B10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.3109\/09513590903511505","article-title":"Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers","volume":"26","author":"Paris","year":"2010","journal-title":"Gynecol Endocrinol"},{"issue":"4","key":"2023111712400395200_dgad377-B11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0015-0282(00)01798-2","article-title":"Candidate gene analysis in premature pubarche and adolescent hyperandrogenism","volume":"75","author":"Witchel","year":"2001","journal-title":"Fertil Steril"},{"key":"2023111712400395200_dgad377-B12","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8984365","article-title":"Variations in the 3'UTR Of the CYP21A2 gene in heterozygous females with hyperandrogenaemia","volume":"2017","author":"Neocleous","year":"2017","journal-title":"Int J Endocrinol"},{"issue":"5","key":"2023111712400395200_dgad377-B13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1055\/s-2008-1081209","article-title":"The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism","volume":"117","author":"Kelestimur","year":"2009","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"4","key":"2023111712400395200_dgad377-B14","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM198507253130404","article-title":"Late-onset adrenal hyperplasia in hirsutism","volume":"313","author":"Kuttenn","year":"1985","journal-title":"N Engl J Med"},{"issue":"4","key":"2023111712400395200_dgad377-B15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/(SICI)1096-8628(19980401)76:4<337::AID-AJMG9>3.0.CO;2-M","article-title":"Identification of heterozygotic carriers of 21-hydroxylase deficiency: sensitivity of ACTH stimulation tests","volume":"76","author":"Witchel","year":"1998","journal-title":"Am J Med Genet"},{"issue":"6","key":"2023111712400395200_dgad377-B16","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0022-3476(77)80561-1","article-title":"Identification of heterozygote carriers of congenital adrenal hyperplasia by radioimmunoassay of serum 17-OH progesterone","volume":"90","author":"Krensky","year":"1977","journal-title":"J Pediatr"},{"key":"2023111712400395200_dgad377-B17","first-page":"507","article-title":"Detection of heterozygous carriers for 21-hydroxylase deficiency by plasma 21-deoxycortisol measurement","volume":"116","author":"Gourmelen","year":"1987","journal-title":"Acta Endocrinol"},{"issue":"4","key":"2023111712400395200_dgad377-B18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1210\/jcem-66-4-659","article-title":"Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia","volume":"66","author":"Fiet","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"2023111712400395200_dgad377-B19","first-page":"187","article-title":"Evaluation of 21-deoxycortisol as a marker for the detection of heterozygous carriers of 21-hydroxylase deficiency","volume":"44","author":"Milewicz","year":"1993","journal-title":"Endokrynol Pol"},{"issue":"6","key":"2023111712400395200_dgad377-B20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/0022-4731(89)90426-3","article-title":"Radioimmunoassay of plasma 21-deoxycortisol","volume":"33","author":"Nahoul","year":"1989","journal-title":"J Steroid Biochem"},{"issue":"2","key":"2023111712400395200_dgad377-B21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF03348240","article-title":"Serum 21-deoxycortisol and 17-hydroxypregnenolone in parents of patients with congenital adrenal hyperplasia","volume":"3","author":"Cassorla","year":"1980","journal-title":"J Endocrinol Invest"},{"key":"2023111712400395200_dgad377-B22","first-page":"186","article-title":"A liquid chromatography\/tandem mass spectometry profile of 16 serum steroids, including 21-deoxycortisol and 21-deoxycorticosterone, for management of congenital adrenal hyperplasia","volume":"1","author":"Fiet","year":"2017","journal-title":"J Endocr Soc"},{"issue":"6","key":"2023111712400395200_dgad377-B23","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1365-2265.2010.03871.x","article-title":"Superior discriminating value of ACTH-stimulated serum 21-deoxycortisol in identifying heterozygote carriers for 21-hydroxylase deficiency","volume":"73","author":"Costa-Barbosa","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023111712400395200_dgad377-B24","first-page":"587","article-title":"Zona fasciculata 21-hydroxysteroids and precursor-to-product ratios in 21-hydroxylase deficiency: further characterization of classic and non-classic patients and heterozygote carriers","volume":"34","author":"Costa-Barbosa","year":"2011","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2023111712400395200_dgad377-B25","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1530\/EJE-14-1084","article-title":"LC-MS\/MS based determination of basal- and ACTH-stimulated plasma concentrations of 11 steroid hormones: implications for detecting heterozygote CYP21A2 mutation carriers","volume":"173","author":"Kulle","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2023111712400395200_dgad377-B26","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1210\/jc.2006-2890","article-title":"Newborn screening for congenital adrenal hyperplasia: additional steroid profile using liquid chromatography-tandem mass spectrometry","volume":"92","author":"Janzen","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2023111712400395200_dgad377-B27","volume-title":"Description of the LC-MS\/MS Method PathWest QEII Laboratory Nedlands WA","author":"Zhang","year":"2023"},{"issue":"10","key":"2023111712400395200_dgad377-B28","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ins.2009.12.010","article-title":"Advanced nonparametric tests for multiple comparisons in the design of experiments in computational intelligence and data mining: experimental analysis of power","volume":"180","author":"Garc\u00eda","year":"2010","journal-title":"Inf Sci (NY)"},{"key":"2023111712400395200_dgad377-B29","author":""},{"issue":"4","key":"2023111712400395200_dgad377-B30","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/cen.14550","article-title":"Reassessment of predictive values of ACTH-stimulated serum 21-deoxycortisol and 17-hydroxyprogesterone to identify CYP21A2 heterozygote carriers and nonclassic subjects","volume":"95","author":"Costa-Barbosa","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023111712400395200_dgad377-B31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/EJE-20-0129","article-title":"Androgen excess and diagnostic steroid biomarkers for nonclassic 21-hydroxylase deficiency without cosyntropin stimulation","volume":"183","author":"Turcu","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2023111712400395200_dgad377-B32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s40618-020-01235-3","article-title":"Steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency in a population of PCOS with suspicious levels of 17OH-progesterone","volume":"43","author":"Oriolo","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"Suppl 1","key":"2023111712400395200_dgad377-B33","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.fertnstert.2006.03.004","article-title":"Nonclassic adrenal hyperplasia","volume":"86","author":"Moran","year":"2006","journal-title":"Fertil Steril"},{"issue":"3","key":"2023111712400395200_dgad377-B34","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1210\/jc.2009-1383","article-title":"Fertility in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"95","author":"Bidet","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2023111712400395200_dgad377-B35","first-page":"635","article-title":"Fertility in women with late-onset adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"74","author":"Feldman","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023111712400395200_dgad377-B36","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.fertnstert.2022.05.012","article-title":"Adrenal steroid profiling as a diagnostic tool to differentiate polycystic ovary syndrome from nonclassic congenital adrenal hyperplasia: pinpointing easy screening possibilities and normal cutoff levels using liquid chromatography tandem mass spectrometry","volume":"118","author":"Ueland","year":"2022","journal-title":"Fertil Steril"},{"issue":"5","key":"2023111712400395200_dgad377-B37","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1055\/s-0032-1324723","article-title":"An update on prenatal diagnosis and treatment of congenital adrenal hyperplasia","volume":"30","author":"New","year":"2012","journal-title":"Semin Reprod Med"},{"issue":"1","key":"2023111712400395200_dgad377-B38","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s004390050586","article-title":"Exhaustive screening of the 21-hydroxylase gene in a population of hyperandrogenic women","volume":"101","author":"Blanch\u00e9","year":"1997","journal-title":"Hum Genet"},{"issue":"2","key":"2023111712400395200_dgad377-B39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/bmme.1997.2632","article-title":"Hyperandrogenism and manifesting heterozygotes for 21-hydroxylase deficiency","volume":"62","author":"Witchel","year":"1997","journal-title":"Biochem Mol Med"},{"key":"2023111712400395200_dgad377-B40","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(04)17344-3","article-title":"P450 oxidoreductase deficiency","volume":"364","author":"Miller","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"2023111712400395200_dgad377-B41","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1210\/jc.2006-2345","article-title":"Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency","volume":"92","author":"Scott","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2023111712400395200_dgad377-B42","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1093\/humrep\/dew218","article-title":"The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis","volume":"31","author":"Bozdag","year":"2016","journal-title":"Hum Reprod"},{"issue":"5","key":"2023111712400395200_dgad377-B43","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1530\/EJE-15-1181","article-title":"Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency","volume":"174","author":"Turcu","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"2023111712400395200_dgad377-B44","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41431-020-0653-5","article-title":"EMQN Best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency","volume":"28","author":"Baumgartner-Parzer","year":"2020","journal-title":"Eur J Hum Genet"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad377\/50836936\/dgad377.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/e1560\/53480912\/dgad377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/e1560\/53480912\/dgad377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T13:41:30Z","timestamp":1700228490000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/12\/e1560\/7207509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":44,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6,26]]},"published-print":{"date-parts":[[2023,11,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad377","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,6,26]]}}}